Diseases are most easily prevented, or treated effectively, if they are detected early. TGen’s Early Detection and Prevention Division is dedicated to identifying diseases at their earliest stages by leveraging advanced -omic technologies, surpassing the capabilities of traditional methods. By transforming these discoveries into innovative diagnostic and therapeutic solutions, we strive to stop diseases before they start, enhance patient outcomes, and save lives.
A team of researchers from Translational Genomics Research Institute (TGen), part of City of Hope, Ethos Discovery and Tufts University, has launched an extensive genomics and proteomics profiling study on Canine Osteosarcoma, B-cell Lymphoma, and Soft Tissue Sarcoma (STS). This initiative is part of the Canine Cancer Genome Project (CCGP), originally funded by the Blue Buffalo Foundation and Animal Cancer Foundation (ACF).
Read ArticleA team of researchers co-led by TGen, part of City of Hope, have uncovered important molecular signatures that could help predict the progression of hepatic steatosis, a liver condition linked to obesity and other metabolic disorders.
Read ArticleTGen announced the appointment of John Fryer, Ph.D., as a professor in the Division of Bioinnovation and Genome Sciences and director of the newly established Center for Accelerated Nanotherapeutics. The appointment further advances TGen’s mission to accelerate leading-edge research in the fight against Alzheimer’s and other devastating diseases.
Read ArticleGlyphosate exposure linked to Alzheimer’s disease-like pathology in pre-clinical models
Read ArticleNicholas Banovich, Ph.D., associate professor and division director of Bioinnovation and Genome Sciences at TGen, part of City of Hope, will lead or co-lead three collaborative grants totaling over $22 million, with $8.2 million supporting research at TGen.
Read Article